PYY 3-36
Peptide YY 3-36 · PYY(3-36) · Peptide tyrosine tyrosine
An endogenous gut peptide released after meals that potently suppresses appetite by acting on the hypothalamus, with research interest in obesity treatment and metabolic health.
Half-Life
~7 minutes (IV); longer with SC administration (~30-60 min)
MW
4049.6 Da
Amino Acids
34 AA
Evidence
High Evidence
Regulatory Status
Endogenous hormone. Not FDA-approved as a therapeutic. Multiple pharmaceutical attempts to develop PYY 3-36 analogs (Nastech intranasal formulation, NN9747) have not reached market. Research chemical available for preclinical studies.
In Plain English
One of your gut's "I'm full" signals — released after meals in proportion to how much you eat, especially after high-protein meals. PYY 3-36 travels to your brain's hunger center and turns off the hunger-promoting neurons. Researchers are interested in it for obesity treatment alongside GLP-1 drugs.
Overview
PYY 3-36 is the physiologically active truncated form of PYY (Peptide YY), a 36-amino acid neuropeptide of the NPY/PP family produced by L-cells in the ileum, colon, and rectum. PYY 3-36 is generated from full-length PYY by dipeptidyl peptidase IV (DPP-IV) cleavage of the N-terminal Tyr-Pro. It is released into circulation proportionally to meal caloric content and macronutrient composition, with protein meals producing the strongest response. PYY 3-36 acts at Y2 receptors in the arcuate nucleus to inhibit NPY/AgRP (orexigenic) neurons, reducing appetite and food intake for 6-12 hours post-meal. Clinical studies demonstrate 30-33% reductions in ad libitum food intake following IV or intranasal PYY 3-36 infusion. It is considered a key satiety hormone alongside GLP-1, CCK, and leptin.
Common Formats
- Research-grade synthetic peptide (IV or SC research use)
- Intranasal formulation (studied in clinical trials)
Storage Notes
Lyophilized: -20°C long-term. Reconstituted in PBS or 0.1% BSA/PBS: stable 1-2 weeks at 4°C. Avoid repeated freeze-thaw. pH 4-7 optimal.
Looking for multi-compound protocols?
Browse educational protocol discussions that include PYY 3-36.
Related Compounds
Semaglutide
A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.
Liraglutide
A once-daily GLP-1 receptor agonist with FDA approval for T2D and obesity, the predecessor to semaglutide with strong clinical evidence.
Cagrilintide
A long-acting amylin analogue in Phase III clinical trials, studied for weight management and metabolic disease, often in combination with semaglutide (CagriSema) for synergistic weight reduction.
Ghrelin
The endogenous "hunger hormone" and natural GH secretagogue produced primarily in the stomach, with broad roles in appetite, energy balance, GH release, and metabolic regulation.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.